Erbitux Adverse Reactions

The main undesirable effects of cetuximab are skin reactions, which occur in more than 80% of patients, hypomagnesaemia which occurs in more than 10% of patients and infusion-related reactions, which occur with mild to moderate symptoms in more than 10% of patients and with severe symptoms in more than 1% of patients.
The following definitions apply to the frequency terminology used hereafter: Very common (≥1/10); Common (≥1/100, < 1/10); Uncommon (≥1/1,000, < 1/100); Rare (≥1/10,000, < 1/1,000); Very rare (< 1/10,000); Frequency not known (cannot be estimated from the available data).
Metabolism and nutrition disorders: Very common: Hypomagnesaemia.
Common: Dehydration, in particular secondary to diarrhoea or mucositis; hypocalcaemia; Anorexia which may lead to weight decrease.
Nervous system disorders: Common: Headache.
Frequency not known: Aseptic meningitis.
Eye disorders: Common: Conjunctivitis.
Uncommon: Blepharitis, keratitis.
Vascular disorders: Uncommon: Deep vein thrombosis.
Respiratory, thoracic and mediastinal disorders: Uncommon: Pulmonary embolism.
Rare: Interstitial lung disease, which may be fatal.
Gastrointestinal disorders: Common: Diarrhoea, nausea, vomiting.
Hepatobiliary disorders: Very common: Increase in liver enzyme levels (ASAT, ALAT, AP).
Skin and subcutaneous tissue disorders: Very common: Skin reactions may develop in more than 80% of patients and mainly present as acne-like rash and/or, less frequently, as pruritus, dry skin, desquamation, hypertrichosis, or nail disorders (e.g. paronychia). Approximately 15% of the skin reactions are severe, including single cases of skin necrosis. The majority of skin reactions develop within the first three weeks of therapy. They generally resolve, without sequelae, over time following cessation of treatment if the recommended adjustments in dose regimen are followed (see Precautions).
Very rare: Stevens-Johnson syndrome/toxic epidermal necrolysis.
Frequency not known: Skin lesions induced by cetuximab may predispose patients to superinfections (e.g. with S. aureus), which may lead to subsequent complications, e.g. cellulitis, erysipelas, or, potentially with fatal outcome, staphylococcal scalded skin syndrome, necrotizing fasciitis or sepsis.
General disorders and administration site conditions: Very common: Mild or moderate infusion-related reactions (see Precautions). Mucositis, in some cases severe. Mucositis may lead to epistaxis.
Common: Severe infusion-related reactions may occur, in some cases with fatal outcome (see Precautions); fatigue.
Additional information: Overall, no clinically relevant difference between genders was observed.
Combination treatment: When Erbitux is used in combination with chemotherapeutic agents, also refer to their respective product information.
In combination with platinum-based chemotherapy, the frequency of severe leukopenia or severe neutropenia may be increased, and thus may lead to a higher rate of infectious complications such as febrile neutropenia, pneumonia and sepsis compared to platinum-based chemotherapy alone (see Precautions).
In combination with fluoropyrimidines, the frequency of cardiac ischaemia including myocardial infarction and congestive heart failure as well as the frequency of hand-foot syndrome (palmar-plantar erythrodysaesthesia) were increased compared to that with fluoropyrimidines.
In combination with local radiation therapy of the head and neck area, additional undesirable effect were those typical of radiation therapy (such as mucositis, radiation dermatitis, dysphagia or leukopenia, mainly presenting as lymphocytopenia). In a randomised controlled clinical study with 424 patients, reporting rates of severe acute radiation dermatitis and mucositis as well as of late radiation-therapy-related events were slightly higher in patients receiving radiation therapy in combination with cetuximab than in those receiving radiation therapy alone.